Bio-Rad Laboratories (NYSE:BIO) versus SeqLL (NASDAQ:SQL) Financial Analysis

[ad_1]


Bio-Rad Laboratories (NYSE:BIO – Get Rating) and SeqLL (NASDAQ:SQL – Get Rating) are both medical companies, but which is the better stock? We’ll compare the two companies based on their risk strength, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares the net margins, return on equity and return on assets of Bio-Rad Laboratories and SeqLL.

Net margins Return on equity return on assets
Bio-Rad Laboratories -3.49% 3.66% 2.77%
SeqLL N / A N / A N / A

Analyst Notes

This is a summary of the current recommendations for Bio-Rad Laboratories and SeqLL, as provided by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Bio-Rad Laboratories 0 0 3 0 3.00
SeqLL 0 0 1 0 3.00

Bio-Rad Laboratories currently has a consensus target price of $793.33, indicating a potential upside of 48.13%. SeqLL has a consensus target price of $3.00, indicating a potential upside of 289.66%. Given the higher possible upside of SeqLL, analysts clearly believe that SeqLL is more favorable than Bio-Rad Laboratories.

Institutional and insider ownership

63.7% of Bio-Rad Laboratories shares are held by institutional investors. By comparison, 2.1% of SeqLL’s shares are held by institutional investors. 27.4% of the shares of Bio-Rad Laboratories are held by insiders of the company. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a company will outperform the market over the long term.

Valuation and benefits

This table compares the gross revenue, earnings per share (EPS), and valuation of Bio-Rad Laboratories and SeqLL.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Bio-Rad Laboratories $2.92 billion 5.49 $4.25 billion ($4.88) -109.75
SeqLL $210,000.00 43.59 -$3.70 million N / A N / A

Bio-Rad Laboratories has higher revenues and profits than SeqLL.

Summary

Bio-Rad Laboratories beats SeqLL on 7 out of 10 factors compared between the two stocks.

Company Profile Bio-Rad Laboratories (Get a rating)

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada and Latin America. The Company operates through the Life Sciences and Clinical Diagnostics segments. The Life Sciences segment develops, manufactures and markets a range of laboratory reagents, apparatus and instruments that are used in research techniques, biopharmaceutical production processes and food testing regimes. It focuses on selected segments of the life science market in the areas of proteomics, genomics, biopharmaceutical production, cell biology and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, computer systems, test kits and specialty quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments and software that address specific niches in the in vitro diagnostic testing market. It sells its products to reference laboratories, hospital laboratories, public neonatal screening establishments, laboratories in medical practices and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze and purify components. The Company offers its products through its direct sales force, as well as through distributors, agents, brokers and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

SeqLL Company Profile (Get a rating)

SeqLL Inc. is a worldwide life science research and instrumentation services company. The company designs, develops and manufactures genetic analysis technologies. It offers a true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has entered into a collaboration agreement with Bernstein Lab, Ting Lab, Jackson Lab for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government institutions, hospitals and medical centers, pharmaceutical companies and biotechnology companies and not-for-profit research organizations. The company was founded in 2013 and is based in Billerica, Massachusetts.



Receive daily news and reviews for Bio-Rad Laboratories – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Bio-Rad Laboratories and related companies with MarketBeat.com’s FREE daily newsletter.

[ad_2]
Source link

Comments are closed.